- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04036253
Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease
A Randomized, Comparative Study of HEMAX PFS® Versus EPREX/ ERYPO® in the Treatment of Anemia With Epoetin Alfa in Patients With Predialysis Chronic Kidney Disease
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina
- CIMEL
-
Buenos Aires, Argentina
- CEMEDIC
-
Buenos Aires, Argentina
- CEREHA
-
Caba, Argentina
- Hospital Britanico de Buenos Aires
-
Caba, Argentina
- CIPREC (Centro de Investigación y Prevención Cardiovascular)
-
Caba, Argentina
- GEMA Consultorio
-
Caba, Argentina
- Hospital Argerich
-
Caba, Argentina
- Hospital Durand
-
Caba, Argentina
- Hospital Fernandez
-
Caba, Argentina
- Hospital Ramos Mejia
-
-
-
-
-
Asunción, Paraguay
- IPHIC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients older than 18 years
- Patients with pre-dialysis chronic renal failure (CRF) defined by a glomerular filtration rate (calculated with the Modification of Diet in Renal Disease Study formula) ≥15 ml/ min and <60 ml/ min, by 1.73 m2
- Anemic patients that should be treated and levels of hemoglobin <10.5 g/dl and ≥ 7.5 g/dl.
- Patients that have the will and capacity to sign a written inform consent.
- Post-menopause women for at least 2 years, or sterile by surgery for at least 6 months. Women of childbearing age must have a negative pregnancy test at baseline and be willing to get an adequate method of contraception.
Exclusion Criteria:
- Patients that are planned to be on dialysis or have a renal transplant in the following 6 months.
- Transferrin iron Saturation < 20%.
- Etiology of renal failure (as secondary to autoimmune diseases) that, to the judge to the physician, can affect the normal development of the protocol.
- Active bleeding or history of hemorrhage that have led to a significative decrease of hematocrit in the last 30 days.
- Non-controlled hypertension (≥160 mm Hg of systolic pressure and/or ≥100 mm Hg of diastolic pressure with anti-hypertensive treatment).
- Anemia caused by any other cause than renal disease.
- Having a transfusion in the last 3 months before basal visit or during screening.
- Treatment with an erythropoiesis stimulant in the last 3 months before basal visit or screening.
- Increase risk of thromboembolic disease: history of arterial thromboembolia (stroke, transient ischemic attack, Acute coronary syndrome, etc.) in the last 6 months or venous in the last 12 months before screening; surgery in the last month before screening; prolong immobilization or orthopedic surgery programmed in the following 6 months or any other condition that to the judge of the investigator can increase the risk of thromboembolism.
- Hematological disease or myelodysplastic syndrome or history of hematological neoplasm or solid tumor in the last 5 years.
- History of congestive heart failure
- Pregnancy or breast feeding
- Refuse to participate in the protocol or any medical condition, that in the investigator opinion, is significant to prevent the participant from being included in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Eprex/Erypo
Receive EPREX/ ERYPO® subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below. There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks. |
Prefilled syringes of erythropoietin
|
EXPERIMENTAL: Hemax PFS
receive HEMAX® PFS subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below. There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks. |
Prefilled syringes of erythropoietin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy Evaluation through the increase of Hemoglobin levels
Time Frame: 12 weeks of treatment
|
Evaluate the efficacy of treatment with erythropoietin alfa through increased levels of hemoglobin from baseline value to the mean value of the 8 to 12 weeks of treatment, comparing patients treated with HEMAX® PFS versus EPREX/ ERYPO®.
|
12 weeks of treatment
|
Adverse Events and Adverse Reactions (safety and tolerability) at week 12
Time Frame: 12 weeks of treatment
|
Evaluate the safety through the incidence of adverse events and adverse reactions after 12 and 24 weeks of treatment, comparing patients treated with HEMAX® PFS versus those treated with EPREX/ ERYPO®.
|
12 weeks of treatment
|
Adverse Events and Adverse Reactions (safety and tolerability) at week 24
Time Frame: 24 weeks of treatment
|
Evaluate the safety through the incidence of adverse events and adverse reactions after 12 and 24 weeks of treatment, comparing patients treated with HEMAX® PFS versus those treated with EPREX/ ERYPO®.
|
24 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of responders patients
Time Frame: 12 weeks of treatment
|
Evaluate the efficacy of treatment with erythropoietin alfa through the percentage of responder patients (increase of Hb ≥ 1g/ dl) after 12 weeks of treatment, comparing patients treated with HEMAX® PFS versus those treated with EPREX/ ERYPO®.
|
12 weeks of treatment
|
Percentage of patients that required any Transfusion
Time Frame: 12 weeks of treatment
|
Evaluate the percentage of transfusional requirement after 12 weeks of treatment, comparing patients treated with HEMAX PFS versus those treated with EPREX/ ERYPO®.
|
12 weeks of treatment
|
Change of Hemoglobin level at week 12 of treatment
Time Frame: Intragroup efficacy until week 12
|
Evaluate the efficacy between arms (HEMAX® PFS and EPREX/ ERYPO®) of treatment with erythropoietin alfa through the change in the level of hemoglobin from baseline in every visit until the week 12 visit.
|
Intragroup efficacy until week 12
|
Evaluate the efficacy between arms 24 weeks: week doses in the titration
Time Frame: Intragroup efficacy until week 24
|
Evaluate the efficacy between arms (HEMAX® PFS and EPREX/ ERYPO®) of the change from the twice - a - week doses in the titration phase to a weekly dose in the maintenance phase through the changes in the hemoglobin levels from week 12 to weeks 16, 20 and 24 of treatment
|
Intragroup efficacy until week 24
|
Incidence of anti-drug antibodies (immunogenicity)
Time Frame: 12 and 24 weeks of treatment
|
An anti-erythropoietin alfa antibody determination will be performed to evaluate treatment immunogenicity at week 12 and 24 visit
|
12 and 24 weeks of treatment
|
Concentration of Hepcidin
Time Frame: 24 weeks of treatment
|
Hepcidin will be analyzed by ELISA at baseline, week 12 and 24 in order to evaluate the treatment response.
|
24 weeks of treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BIOS-HPFS-0115
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia of Chronic Kidney Disease
-
Medical University of ViennaCompletedAnemia of Chronic Kidney DiseaseAustria
-
Dong-A ST Co., Ltd.UnknownAnemia of Chronic Kidney DiseaseTurkey
-
Chong Kun Dang PharmaceuticalCompletedAnemia of Chronic Kidney Disease
-
Rufaida MazahirCompletedAnemia of Chronic Kidney DiseaseIndia
-
Helwan UniversityCompletedAnemia of Chronic Kidney Disease | Chronic Renal Failure | Chronic Renal Failure AnemiaEgypt
-
Shenzhen Second People's HospitalRecruiting
-
JW PharmaceuticalCompletedAnemia of Chronic Kidney DiseaseKorea, Republic of
-
Xiamen Amoytop Biotech Co., Ltd.First Affiliated Hospital of Zhejiang UniversityCompletedRenal Anemia of Chronic Kidney DiseaseChina
-
Hoffmann-La RocheCompletedRenal Anemia of Chronic Kidney DiseaseCroatia
Clinical Trials on Erythropoietin alfa
-
University of CambridgeHoffmann-La Roche; Roche Foundation of Anemia Research (RoFAR, Switzerland)CompletedAneurysmal Subarachnoid HemorrhageUnited Kingdom
-
Bundang CHA HospitalLG Life SciencesCompleted
-
Dong-A ST Co., Ltd.Unknown
-
University Eye Hospital, FreiburgGerman Federal Ministry of Education and ResearchCompleted
-
Chugai PharmaceuticalCompletedChemotherapy Induced Anemia
-
M.D. Anderson Cancer CenterCompleted
-
SandozHexal AGCompletedChronic Kidney Disease | End-stage Renal Disease | AnaemiaAustria, France, Germany, Italy, Poland, Romania, Slovenia, Spain, Switzerland, United Kingdom
-
Angde Biotech Pharmaceutical Co., Ltd.Recruiting
-
Northwestern UniversityActive, not recruitingLiver Transplant RejectionUnited States
-
Alexandria UniversityCompleted